134 related articles for article (PubMed ID: 15715085)
1. Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
Zainelli GM; Dudek NL; Ross CA; Kim SY; Muma NA
J Neuropathol Exp Neurol; 2005 Jan; 64(1):58-65. PubMed ID: 15715085
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase cross-links in intranuclear inclusions in Huntington disease.
Zainelli GM; Ross CA; Troncoso JC; Muma NA
J Neuropathol Exp Neurol; 2003 Jan; 62(1):14-24. PubMed ID: 12528814
[TBL] [Abstract][Full Text] [Related]
3. Calmodulin regulates transglutaminase 2 cross-linking of huntingtin.
Zainelli GM; Ross CA; Troncoso JC; Fitzgerald JK; Muma NA
J Neurosci; 2004 Feb; 24(8):1954-61. PubMed ID: 14985437
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of interrupting the binding of calmodulin to mutant huntingtin.
Dudek NL; Dai Y; Muma NA
J Neuropathol Exp Neurol; 2008 Apr; 67(4):355-65. PubMed ID: 18379433
[TBL] [Abstract][Full Text] [Related]
5. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
[TBL] [Abstract][Full Text] [Related]
6. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.
Munsie L; Caron N; Atwal RS; Marsden I; Wild EJ; Bamburg JR; Tabrizi SJ; Truant R
Hum Mol Genet; 2011 May; 20(10):1937-51. PubMed ID: 21355047
[TBL] [Abstract][Full Text] [Related]
7. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
8. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.
Kim M; Lee HS; LaForet G; McIntyre C; Martin EJ; Chang P; Kim TW; Williams M; Reddy PH; Tagle D; Boyce FM; Won L; Heller A; Aronin N; DiFiglia M
J Neurosci; 1999 Feb; 19(3):964-73. PubMed ID: 9920660
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.
Karpuj MV; Garren H; Slunt H; Price DL; Gusella J; Becher MW; Steinman L
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7388-93. PubMed ID: 10377424
[TBL] [Abstract][Full Text] [Related]
10. Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin.
Ruan Q; Quintanilla RA; Johnson GV
J Neurochem; 2007 Jul; 102(1):25-36. PubMed ID: 17403029
[TBL] [Abstract][Full Text] [Related]
11. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates.
Chun W; Lesort M; Tucholski J; Ross CA; Johnson GV
J Cell Biol; 2001 Apr; 153(1):25-34. PubMed ID: 11285271
[TBL] [Abstract][Full Text] [Related]
12. Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain.
Toneff T; Mende-Mueller L; Wu Y; Hwang SR; Bundey R; Thompson LM; Chesselet MF; Hook V
J Neurochem; 2002 Jul; 82(1):84-92. PubMed ID: 12091468
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.
Kahlem P; Green H; Djian P
Mol Cell; 1998 Mar; 1(4):595-601. PubMed ID: 9660943
[TBL] [Abstract][Full Text] [Related]
14. ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line.
Liang Y; Jiang H; Ratovitski T; Jie C; Nakamura M; Hirschhorn RR; Wang X; Smith WW; Hai T; Poirier MA; Ross CA
Brain Res; 2009 Aug; 1286():221-9. PubMed ID: 19559011
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase is increased in Huntington's disease brain.
Lesort M; Chun W; Johnson GV; Ferrante RJ
J Neurochem; 1999 Nov; 73(5):2018-27. PubMed ID: 10537061
[TBL] [Abstract][Full Text] [Related]
16. Huntingtin processing in pathogenesis of Huntington disease.
Qin ZH; Gu ZL
Acta Pharmacol Sin; 2004 Oct; 25(10):1243-9. PubMed ID: 15456523
[TBL] [Abstract][Full Text] [Related]
17. Nuclear targeting of mutant Huntingtin increases toxicity.
Peters MF; Nucifora FC; Kushi J; Seaman HC; Cooper JK; Herring WJ; Dawson VL; Dawson TM; Ross CA
Mol Cell Neurosci; 1999 Aug; 14(2):121-8. PubMed ID: 10479410
[TBL] [Abstract][Full Text] [Related]
18. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A.
Hu H; McCaw EA; Hebb AL; Gomez GT; Denovan-Wright EM
Eur J Neurosci; 2004 Dec; 20(12):3351-63. PubMed ID: 15610167
[TBL] [Abstract][Full Text] [Related]
19. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
[TBL] [Abstract][Full Text] [Related]
20. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
